STOCKS TELEGRAPH

Tag: CRIS

  • Curis Inc. (CRIS) stock Bullish Pre-Market on Data from its Clinical Trials

    On January 06, Curis Inc. (CRIS) announced updated data from Phase ½ Study of CA-4948 and initial clinical data from Phase 1 Study of CI-8993. Consequently, the stock became bullish in the pre-market while it was in the red during regular trading.

    In the regular session, CRIS stock lost a huge 27.64% at its closing price of $3.4950 at 9.72 million shares. Following the announcement, the stock recovered to gain 5.58% in the pre-market. Hence, the stock was trading at $3.69 per share.

    CRIS’ Data Updates

    On Thursday, the company provided positive updated data from its ongoing open-label Phase ½ study of CA-4948. This trial is studying CA-4948 as monotherapy in relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Moreover, CRIS also provided initial clinical data from the Phase 1 study of CI-8993 in patients with R/R solid tumors.

    CA-4948 Data

    According to the data, CA-4948 demonstrated a well-tolerated general safety profile at multiple dose levels. In addition, there were no irreversible or unmanageable adverse events.

    Previously, the company had provided the efficacy data of CA-4948 in patients with FLT3 mutation. The expanded data set of this patient population also demonstrated a favorable safety and anti-cancer activity profile. Hence, the company plans to start discussions with the FDA for a rapid registrational path for CA-4948, in the first half of 2022. Furthermore, CRIS would be providing additional data from the study at a medical meeting in 2022.

    CI-8993 Data

    As per the preliminary preclinical data, CI-8993 has so far demonstrated a general safety profile and no toxicities related to dosage. So far, the trial has successfully dose-escalated without any irreversible treatment-related adverse event.

    Further, the company will provide expanded data from the trial in the second half of 2022.

    CRIS: Q3 Financial Results

    On November 09, the company declared its financial results for the third quarter of 2021, which ended on September 30.

    In the third quarter of 2021, the net loss of the company was $11.1 million, against $6.0 million in Q3 of 2020. Resultantly, the net loss per basic share was $0.12 in the third quarter of 2021, against $0.11 in the year-ago quarter.

    CRIS generated revenue of $3.0 million in the third quarter of 2021 against $2.7 million in Q3 of 2020.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.

  • What changed for these 30 stocks in Pre Market Session

    What changed for these 30 stocks in Pre Market Session

    Usio Inc. (USIO) stock soared 41.54% to $2.59 in the pre-market trading after declaring that it has entered into a non-binding Letter of Intent (LOI) to acquire the assets of Information Management Solutions, LLC (IMS).
    NeuroMetrix Inc. (NURO), a Medical Instruments & Supplies company, dropped about -8.03% at $2.75 in pre-market trading Wednesday.
    Cinedigm Corp. (CIDM) stock moved up 43.36 percent to $1.23 in the pre-market trading following a strategic alliance with Spherex to drive Cinedigm’s global growth.
    Recon Technology Ltd. (RCON) stock moved up 112.5 percent to $3.06 in the pre-market trading.
    Curis Inc. (NASDAQ: CRIS) shares are trading up 2.29% at $6.7 at the time of writing after revealing proposed public offering of common Stock. Company’s 52-week ranged between $0.62 to $3.59. Analysts have a consensus price target of $5.
    Gran Tierra Energy Inc. (GTE) lost over -7.04% at $0.355 in pre-market trading Wednesday December 09, 2020. The firm recently declared a financial update and the Company’s 2021 capital budget and production guidance.
    Aurora Cannabis Inc. (ACB) is down more than -0.94% at $10.5 in pre-market hours Wednesday December 09, 2020. The stock had jumped over 1.24% to $10.60 in the last trading session.
    Carnival Corporation & Plc (CCL) is up more than 2.76% at $24.22 in pre-market hours Wednesday December 09, 2020 following declaration of Cunard, a part of Carnival Corporation & plc (CCL), that it has extended its pause in operations due to the ongoing travel constraints in place across the world. The stock had jumped over 1.59% to $23.57 in the last trading session.
    Before the trading started on December 09, 2020, Occidental Petroleum Corporation (OXY) is up 2.56% to reach $19.62 after reporting upsize of previously announced cash tender offers and consent solicitations for certain of its senior notes. It has been trading in a 52-week range of $8.52 to $47.58.
    Virgin Galactic Holdings Inc. (SPCE) stock soared 2.55% to $34.24 in the pre-market trading. The most recent rating by Goldman, on October 23, 2020, is a Neutral.
    Eastman Kodak Company (NYSE: KODK) shares are trading down -4.04% at $10.7 at the time of writing after getting clean chit from U.S government regarding a government loan. Company’s 52-week ranged between $1.50 to $60.00.
    Moderna Inc. (MRNA) grew over 3.38% at $175.6 in pre-market trading today after declaring that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273.
    Riot Blockchain Inc. (RIOT), a Software – Application company, dropped about -5.78% at $9.3 in pre-market trading Wednesday.
    Norwegian Cruise Line Holdings Ltd. (NCLH), a Travel Services company, rose about 1.95% at $28.7 in pre-market trading Wednesday after announcing partnership with AtmosAir Solutions.
    XPeng Inc. (XPEV) stock moved down -3.72 percent to $46.88 in the pre-market trading following the pricing of follow-on public offering of American depositary shares.
    Cinemark Holdings Inc. (CNK) stock soared 2.26% to $15.36 in the pre-market trading. The most recent rating by Loop Capital, on November 19, 2020, is a Hold.
    Before the trading started on December 09, 2020, Tonix Pharmaceuticals Holding Corp. (TNXP) is up 0.15% to reach $0.65 after declaring results of positive phase 3 RELIEF study for TNX-102 SL 5.6 mg in Fibromyalgia. It has been trading in a 52-week range of $0.39 to $2.46.
    CBAK Energy Technology Inc. (NASDAQ: CBAT) shares are trading up 3.3% at $5.95 at the time of writing following the publication of securities purchase agreement with certain institutional investors for a registered direct placement of approximately $49.2 million of common stock at a price of $5.18 per share. Company’s 52-week ranged between $0.36 to $11.40.
    Jaguar Health Inc. (NASDAQ: JAGX) shares are trading down -4.84% at $0.3798 at the time of writing. Company’s 52-week ranged between $0.19 to $1.08. Analysts have a consensus price target of $2.
    United Airlines Holdings Inc. (UAL) grew over 1.88% at $49.96 in pre-market trading today after launching virtual, on demand customer service at the airport.
    GameStop Corp. (GME) is down more than -17.59% at $13.96 in pre-market hours Wednesday December 09, 2020 after releasing results for the third quarter ended October 31, 2020. The stock had jumped over 3.61% to $16.94 in the last trading session.
    Before the trading started on December 09, 2020, ADMA Biologics Inc. (ADMA) is up 4.31% to reach $2.18. It has been trading in a 52-week range of $1.45 to $4.65.
    Before the trading started on December 09, 2020, HEXO Corp. (HEXO) is down -2.91% to reach $1.0. The firm recently reported downward revision to its proposed share consolidation ratio. It has been trading in a 52-week range of $0.35 to $2.30.
    United Microelectronics Corporation (UMC) is up more than 1.37% at $8.88 in pre-market hours Wednesday December 09, 2020 afterreporting unaudited net sales for the month of November 2020. The stock had dropped over -3.10% to $8.76 in the last trading session.
    Apache Corporation (NASDAQ: APA) shares are trading up 1.08% at $14.92 at the time of writing following the board of directors of Apache Corporation (APA) has declared a regular cash dividend on the company’s common shares. Company’s 52-week ranged between $3.80 to $33.77. Analysts have a consensus price target of $16.
    Phunware Inc. (PHUN) stock moved down -3.28 percent to $0.81 in the pre-market trading after revealing its receipt of the Privacy Shield certification.
    Sorrento Therapeutics Inc. (SRNE) stock soared 9.62% to $8.66 in the pre-market trading after declaring that it has received CLIA Licensure from the State of California that permits testing of clinical samples. The most recent rating by H.C. Wainwright, on July 31, 2020, is a Buy.
    Sesen Bio Inc. (SESN) gained over 5.42% at $1.75 in pre-market trading Wednesday December 09, 2020 following the announcement of commercial manufacturing and global supply partnership with Qilu Pharmaceutical.
    Before the trading started on December 09, 2020, Futu Holdings Limited (FUTU) is up 2.27% to reach $44.61 after reporting that a leading global investment firm has agreed to purchase approximately 50,000,000 Class A ordinary shares of the Company in the form of prepaid warrants for an aggregate purchase price of approximately US$260,000,000. It has been trading in a 52-week range of $8.16 to $51.10.
    Westwater Resources Inc. (WWR) stock soared 3.87% to $5.63 in the pre-market trading. The company recently provided an update on progress at its pilot plant operations at Dorfner Anzaplan’s facilities near Amberg, Germany, as well as at facilities in Frankfort, Germany, Chicago, Illinois, and Buffalo, New York.

  • 15 Trending Stocks in Biotechnology Industry

    15 Trending Stocks in Biotechnology Industry

    This year, biotech companies on the stock exchange have skyrocketed. This is no surprise since biotech firms are the leaders in the battle against the coronavirus pandemic. Even with Pfizer’s first vaccine in the UK, investors and pharmaceutical companies are well aware that the race is far ahead.
    Other diseases should not be ignored apart from coronavirus vaccines. The biotech sector is also creating headlines and innovating in areas linked to dementia, cancer, hereditary disorders, etc. Given the above, buyers are probably faced with the difficulty of choosing the best ones to purchase.

    Curis Inc. (NASDAQ:CRIS) shares were trading up 354.86% at $6.55 at the time of writing on Tuesday following announcement of proposed public offering of common stock.

    Curis Inc. (NASDAQ:CRIS) share price went from a low point around $0.62 to briefly over $3.59 in past 52 weeks, though shares have since pulled back to $6.55. CRIS market cap has remained high, hitting $409.70M at the time of writing, giving it price-to-sales ratio of more than 30.

    If we look at the recent analyst rating CRIS, Laidlaw initiated coverage on CRISshares with a Buy rating.

    Lexicon Pharmaceuticals Inc. (LXRX) last closed at $3.08, in a 52-week range of $1.03 to $5.33. Analysts have a consensus price target of $2.37. On November 17, 2020, the firmreported that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

    IGM Biosciences Inc. (IGMS) stock soar by 57.75% to $115.03 after declaringpricing of upsized $200 million public offering. The most recent rating by Robert W. Baird, on July 17, 2020, is at an Outperform.

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Shares headed rising, higher as much as 29.44%. The company will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) The most recent rating by Oppenheimer, on June 27, 2019, is at an Outperform.

    Oncternal Therapeutics Inc. (NASDAQ:ONCT) rose 27.64% after gaining more than $1.1 on Tuesday after reporting updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial.

    Proteostasis Therapeutics Inc. (PTI) last closed at $1.23, in a 52-week range of $0.87 to $4.72. The firm reported on November 16, 2020. a net loss of approximately $8.2 million for the three months ended September 30, 2020, as compared to a net loss of $12.8 million for the same period in the prior year.

    InflaRx N.V. (IFRX) stock soar by 18.27% to $4.79. The most recent rating by SVB Leerink, on November 06, 2020, is at an Outperform.

    Syros Pharmaceuticals Inc. (NASDAQ:SYRS) Shares headed rising, higher as much as 17.47% after closing $90.5 million strategic financing. The most recent rating by H.C. Wainwright, on November 04, 2020, is at a Buy.

    Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) rose 16.28% after gaining more than $0.28 on Tuesday.

    Ampio Pharmaceuticals Inc. (AMPE) last closed at $1.35, in a 52-week range of $0.31 to $1.39. The firm recently revealed that it will conduct its annual meeting in a virtual format only on December 12, 2020 at 9:00 am MST.

    Regulus Therapeutics Inc. (RGLS)stock soar by 15.19% to $0.93 following the closing of $19.4 million private placement of equity. The most recent rating by B. Riley FBR Inc., on March 28, 2018, is at a Neutral.

    Cancer Genetics Inc. (NASDAQ:CGIX) Shares headed rising, higher as much as 14.79%. The most recent rating by Maxim Group, on December 07, 2017, is at a Buy.

    Marinus Pharmaceuticals Inc. (NASDAQ:MRNS) fall -11.85% after losing more than -$1.85 on Tuesday. The healthcare firm lately declared pricing of $70 million public offering of common stock, which is expected to close on or about December 10, 2020.

    iBio Inc. (IBIO) last closed at $1.31, in a 52-week range of $0.19 to $7.45 after declaring pricing of $35 million public offering of common stock. Analysts have a consensus price target of $2.00.

    Vaccinex Inc. (VCNX) stock soar by 14.08% to $2.35. The most recent rating by BTIG Research, on September 23, 2020, is at a Neutral.

  • Curis, Inc. (NASDAQ: CRIS), steaming in the pre-market session on this report

    Curis, Inc. (NASDAQ: CRIS), steaming in the pre-market session on this report

    Curis, Inc. (NASDAQ: CRIS), stock kicked off in pre-market session with a huge jump as it was trading 141.3% to $3.55 after a biotechnology company focused on the development of groundbreaking therapeutics for the cancer therapy, today revealed promising initial findings from its ongoing open-label, single-arm Phase 1 dose-escalation trial in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes of CA-4948, a novel small molecule IRAK4 kinase inhibitor (MDS).

    IRAK4 plays an important role in the signaling pathways of the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) receptors, and these processes are often dysregulated in AML and MDS patients. The long-form of IRAK4 (IRAK4-L) has recently been explored by private entities to be oncogenic and preferentially expressed in more than half of AML and MDS patients. A variety of drivers, including unique spliceosome mutations, are thought to cause this.